A fetus diagnosed with X-linked chronic granulomatous disease was transplanted with Thy-1 ؉ CD34 ؉ cells of paternal origin. The transplant was performed at 14 weeks gestation by ultrasound guided injection into the peritoneal cavity. The fetus was delivered at 38 weeks gestation after an otherwise uneventful pregnancy. Umbilical cord blood was collected and used to determine the level of peripheral blood chimerism as well as levels of functional engrafted cells. 
Advances in fetal diagnosis have spurred the development of fetal therapy as a means to treat birth defects in utero in order to prevent fetal demise or afford an advantageous form of therapy. The imminent success in the sequencing and identification of the genes that comprise the human genome will herald a time when most, if not all, genetic birth defects can be diagnosed before birth. Advances in diagnosis will surely continue to push the frontiers of therapy as parents and clinicians strive for the birth of a healthy infant. In the province of the hematologist, in utero transplantation (IUT) of hematopoietic stem cells (HSCs) is being pursued as a form of fetal therapy with the potential to treat many disorders of the hematopoietic system as well as a range of other diseases that benefit from HSC transplantation. [1] [2] [3] [4] The proposed advantages of IUT pertain to the immaturity of the fetal immune system and the rapid development of the fetal hematopoietic system. 1, [5] [6] [7] [8] Prior to 14 weeks gestation, the fetal immune system has been presumed to be immature and may allow transplantation of HSCs regardless of major histocompatibility antigen (MHC) disparity. Early in the second trimester, at the time of IUT, hematopoiesis is in a period of continued growth in the liver and colonization of the long bones has begun. 9 During this time of rapid expansion of hematopoiesis, donor HSCs might engraft without the need for cytoablative conditioning to provide space for the transplanted HSCs. These hypotheses have been supported by experiments in sheep and other large animals, 8 as well as successes in treating humans with immunodeficiency disorders using IUT. [10] [11] [12] [13] The success of IUT in treating certain immunodeficiencies led us to explore this therapy for the treatment of chronic granulomatous disease (CGD). CGD is a rare, genetically heterogeneous disorder caused by a failure of respiratory burst activation in neutrophils, monocytes, macrophages, and eosinophils. 14 The most common form of CGD results from mutations in the larger 91 kDa subunit of cytochrome b 558 named gp91-phox. 15 Cytochrome b 558 is the membrane-bound redox center of the NADPH oxidase system. The gene that encodes for gp91-phox, CYBB, is located on the X-chromosome at Xp21.1. The severe clinical manifestations of X-linked CGD usually present in the first year of life and can include pneumonias, lymphadenitis, abscesses, skin infections and osteomyelitis. While early diagnosis and treatment have greatly improved the quality and length of life, the CGD patient can still succumb to serious and sometimes fatal infections.
CGD was chosen for IUT because the molecular basis of the disease has been well characterized and the clinical course of the disease is thought to be greatly improved by the presence of as few as 5% (and perhaps even fewer) granulocytes with normal NADPH oxidase activity. This value is based on analysis of heterozygous females that carry the X-linked form of CGD. Random X-chromosome inactivation occurs in these individuals resulting in a variable frequency of cells capable of reactive oxygen species (ROS) production. Individuals with only 5% of peripheral blood cells capable of superoxide production generally remain asymptomatic. Thus, IUT appeared to be a potentially effective form of therapy for CGD since animal studies have achieved donor cell engraftment as high as 15% following IUT. 1 A highly enriched population of HSCs, deeply depleted of T cells, was prepared from paternal bone marrow (BM) to minimize the risk of graft-versus-host disease (GVHD) and to maximize the number of HSCs that can be delivered in a small volume. HSCs were isolated by selection of cells expressing CD34 and Thy-1 (CD90). The safety and effectiveness of transplanting these HSCs in a fetus with X-linked CGD are presented.
Materials and methods

Patient diagnosis
Direct sequencing of DNA from chorionic villus sampling at 12 weeks gestation identified a male fetus with an Xlinked gp91-phox defect that would result in CGD. The specific family mutation was previously identified in a proband and confirmation of the mother's carrier status was shown by DNA sequencing as well as biochemical means prior to this conception. The mother was a 23-year-old, G4P1, Caucasian woman. The parents of the affected fetus received non-directive genetic counseling and were presented with the option of allowing the pregnancy to proceed or to have it electively terminated. The parents selected to continue the pregnancy until term and then were presented with the option of IUT, sponsored by SyStemix (Palo Alto, CA, USA). This transplant was approved by the Committee on Human Research at the University of California at San Francisco and the Federal Food and Drug Administration. Understanding the experimental nature of IUT as a therapy for CGD, the parents elected to proceed with the transplant. The father of the affected fetus volunteered to be the BM donor.
Isolation of paternal HSCs
Standard serum screening of the father found him to be a safe donor. An approximate 300 ml BM collection, containing approximately 2 × 10 9 mononuclear cells, was collected about 24 h prior to IUT. The marrow was filtered and then mixed with approximately 600 ml of a heparinized culture medium for immediate transport to SyStemix. The Thy-1 + CD34 + HSCs were purified by positive selection of CD34 + cells using an Isolex 300SA (Baxter Healthcare Immunotherapy Division, Irvine, CA, USA) 16 and flow cytometric cell sorting to purify the Thy-1 + CD34 + HSCs, as previously described. 17 The cells were stained with monoclonal antibodies (MoAbs) that recognize CD34 and Thy-l (CD90) antigens (SyStemix) and isolated using SyStemix's proprietary dual laser, fluorescence-activated, highspeed clinical cell sorter. 18 Cells were sorted at a rate of 5000-7000 events per second. The Thy-1 + CD34 + cells were sorted directly into a culture tube containing a small volume of SyStemix proprietary culture medium. The purified HSCs were stored overnight at 4°C, counted with a hemocytometer, and resuspended to 1 × 10 7 Thy-1 + CD34
+ cells/ml in a 1 ml volume of sterile PBS. The graft contained 1.19 × 10 7 viable cells (84% Thy-1 + CD34 + ) and 3.57 × 10 3 T cells. The HSC were kept on ice and shipped to the clinical site in a 3 ml capped syringe for infusion.
Transplantation of HSCs and fetal monitoring
The fetus was transplanted at 14 weeks gestation. The HSCs were warmed to ambient temperature prior to infusion. The cells were transplanted under ultrasound guidance through a 22-gauge 5-inch spinal needle inserted through the maternal abdominal wall and uterus and into the peritoneal cavity of the fetus. The pregnancy was monitored by ultrasound, once or twice a week, to week 22 of gestation for indications of fetal movement and heart activity. Thereafter, maternal self-monitoring of fetal movement and/or heart beat was implemented. The pregnancy progressed to term without complications.
Flow cytometric analysis of chimerism using class I major histocompatibility complex (MHC) antigens
Umbilical cord blood (UCB), peripheral blood and BM samples of the patient were analyzed for the presence of donor cells, at birth or 6 months of age, by flow cytometric analysis of class I MHC antigens. Standard immunological typing was used to determine the expression of class I antigens on peripheral blood cells of the mother and father of the patient. An analysis of the human leukocyte antigen (HLA)-A locus of the fetus was also performed from the tissue harvested by chorionic villus sampling (CVS). These analyses revealed that the fetal recipient was HLA-A2 + , an antigen inherited from his mother and not shared with the paternal donor. Further analysis of the patient's UCB revealed that he did not inherit HLA-B7 from the father. Thus, HLA-B7 was used as a positive marker for the donor cells and HLA-A2 was used as a marker of the patient's own cells.
Approximately 100 ml of UCB were harvested immedi-ately following the birth of the patient and collected in ACD-A vacutainers. The UCB was shipped to our laboratories and arrived after less than 18 h. A portion of the UCB was enriched for leukocytes by three rounds of immunomagnetic depletion (using 25 paramagnetic particles/cell) of erythrocytes using an anti-glycophorin A (GPA) MoAb as described. 19 A portion of these GPA − cells was further depleted of remaining red cells and enriched for donor cells by depletion with anti-GPA and anti-HLA-A2-FITC MoAbs. This depletion was accomplished in a single round with 50 paramagnetic particles/cell.
The presence of donor cells among the T cells in the UCB was analyzed after expansion of the UCB T cells in culture. The cultures were started with light-density (Ͻ1.077 g/ml) GPA − UCB cells prepared as described. 19 Cells (5 × 10 7 ) were placed in 50 ml of medium consisting of RPMI and 10% fetal bovine serum (Gemini-BioProducts, Calabasas, CA, USA), 50 g/ml gentamicin (Gibco BRL, Grand Island, NY, USA), and 1 g/ml PHA (Wellcome, Beckenham, UK). Fifty units/ml recombinant human (rh) interleukin (IL)-2 (R&D Systems, Minneapolis, MN, USA) were added on days 2, 4 and 8 of culture. Culture volume was doubled on the fourth day. Cells were harvested on day 9 and analyzed for chimerism and the content of T and NK cells using CD3-PE (Becton Dickinson Immunocytometry Systems (BDIS), San Jose, CA, USA) and CD56-FITC (Exalpha Corporation, Boston, MA, USA).
The progeny of hematopoietic progenitors present in the UCB were also analyzed for evidence of chimerism. Lightdensity GPA − UCB cells (1 × 10
7
) were cultured in a base of serum-deprived medium 20 with 20 ng/ml each of rh kit ligand (KL) (R&D Systems), rhIL-6 (R&D Systems), rh granulocyte colony-stimulating factor (G-CSF) (purchased from Amgen, Thousand Oaks, CA, USA) and rh granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine, purchased from Immunex Corporation (Seattle, WA, USA)). Cells were harvested after 22 days of culture and analyzed for chimerism and the content of myeloid cells using CD14-PE (Caltag Laboratories, South San Francisco, CA, USA) and CD15-FITC (BDIS).
Peripheral blood leukocytes (PBL) from the recipient were analyzed 188 days after birth. Approximately 4 ml of blood was obtained and the presence of donor cells among the total leukocytes was determined by analysis of class I MHC antigens. Total leukocytes were enriched by lysis of the erythrocyte fraction using an ammonium chloride solution. Peripheral blood mononuclear cells (PBMC) were prepared by centrifugation using Lymphoprep. 19 A BM sample was obtained from the IUT recipient at the same time and light-density BM cells were prepared as the PBMC. The high-density fraction of BM cells (Ͻ1.077 g/ml) was also recovered and analyzed for evidence of chimerism after erythrocyte depletion using ammonium chloride lysis.
UCB, peripheral blood and BM of the patient were analyzed by flow cytometry for evidence of chimerism. PBMC from both parents were used as controls for the anti-HLA MoAbs. Cells, 2 × 10 5 to 1 × 10 7 , were stained as described. 21 The antibodies used to identify MHC class I antigens were anti-HLA-A2-FITC (clone CR11351) or anti-
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HLA-A2-FITC (One Lambda, Canoga Park, CA, USA) combined with anti-HLA-B7-PE (PharMingen, San Diego, CA, USA). Only live cells were analyzed based on lack of staining with propidium iodide.
Flow cytometric analysis of NADPH oxidase activity
UCB or peripheral blood were obtained and 0.5 ml was lysed in 10 ml of 1× lyse solution containing 9 g/l NH 4 Cl, 1 g/l KHCO 3 and 37 mg tetrasodium EDTA for 5 min at room temperature and immediately spun at 300 g for 5 min. Remaining cells were washed in 10 ml PBS with 5 mm glucose and 0.1% gelatin and resuspended in 1.5 ml of the same buffer. Dichlorofluorescein diacetate (DCF-DA, 5 m final) or dihydrorhodamine (DHR, 10 m final) were added and the cells incubated for 15 or 10 min, respectively, at 37°C. Catalase was added (552 U/ml final) and the samples were split into two tubes and either stimulated with PMA (phorbol myristate acetate), 100 ng/ml final, or not stimulated (DMSO as control). After 10 and 20 min at 37°C the cells were analyzed by flow cytometry. The strength of the FL-1 fluorescence signal is proportional to the amount of ROS being generated. Sensitivity of the assay was determined by mixing varying amounts of whole blood from a known X-CGD patient with blood from a normal control donor and performing the assay as described above.
Polymerase chain reaction (PCR) analysis of class II MHC antigens
DNA was extracted from peripheral blood, CVS tissue or BM using the QIAmp blood or tissue kit (Qiagen, Valencia, CA, USA). Umbilical cord blood was separated into mononuclear (UCB 1) and non-mononuclear cells (UCB 2) using a Ficoll-Hypaque density gradient prior to DNA isolation using the QIAmp kit. HLA-DRB1 typing was done on DNA isolated from the father (donor), mother, CVS and post-transplant samples using sequence-specific priming. 22 Briefly, genomic DNA was amplified using primers specific for DRB1 allele types. Ten l PCR reactions consisted of 1× PCR Buffer (Perkin-Elmer, Foster City, CA, USA); 500 mm KCl, 15 mm MgCl 2 , 100 mm Tris-HCl pH 8.3, 0.01% w/v gelatin, 5% glycerol, 200 m dNTPs, 1 ng cresol red and ෂ50 ng of template DNA. The PCR profile was as follows: initial denaturation at 94°C for 2 min followed by 10 cycles of 94°C for 10 s, 65°C for 60 s and 20 cycles of 94°C for 10 s, 61°C for 50 s and 72°C for 30 s. The resulting amplicons were visualized by ethidium bromidestained agarose gel electrophoresis. A primer pair specific for all DQB1 alleles was used as a control to check the integrity of the DNA. The sensitivity of the assay was determined by the spiking varying amounts of DNA from a DRB1*15 homozygous typing cell line (SCHU) into DNA from BM21, a DRB1*11 homozygous typing cell line.
Mixed lymphocyte cultures
Peripheral blood was obtained from the infant at 188 days of age as well as from the mother, father and an unrelated donor following consent. PBMC were purified and sus-Bone Marrow Transplantation pended at 1.5 × 10 6 /ml in RPMI medium supplemented with 10% heat inactivated fetal bovine serum, 10 mm HEPES, 1 mm sodium pyruvate, 3 mm l-glutamine, 1 mm non-essential amino acids, 500 g/ml penicillin, 50 g/ml streptomycin and 50 g/ml gentamicin. A portion of the cells from each donor was irradiated with 3000 rad to render them non-proliferative. A 96-well tissue culture plate was set up with wells containing the patient cells as responder (unirradiated) with cells from the mother, father and unrelated donor as the stimulators (irradiated). Mixed cultures were incubated at 37°C in 5% CO 2 for 6 days. 3 Hthymidine was added and plates incubated for another 6 h. Cells were harvested on to filters and thymidine incorporation measured using a liquid scintillation counter. The stimulation index (SI) was calculated as the mean counts of the patient's cells vs stimulator cells divided by the mean counts of the patient's cells alone. The significance of differences in the data were determined using an unpaired Student's t-test.
Analysis of lymphocyte populations in human fetal liver and UCB
Human fetal livers and umbilical cords were obtained from Advanced Bioscience Resources (Alameda, CA, USA) or from our own institute under the approval of the Committee for Human Research at our institute. The gestational age was estimated based on the foot-length of the abortus. Light density (Ͻ1.077 g/ml) fetal liver cells were prepared as described. 19 In some larger (older) liver specimens, red cells were depleted 19 before isolation of the light density cells. UCB cells were obtained by gently squeezing the blood out of the umbilical veins and artery into a small volume of PBS/BSA. The fetal blood samples were concentrated by centrifugation and stained with CD45-PE (Caltag Laboratories) and CD3-FITC (BDIS) or CD56-FITC by the method described. 21 The liver cells were stained with CD3-PE (BDIS) and CD56-FITC (Exalpha, Boston, MA, USA) to determine the frequency of T and NK cells. Control stainings using isotype-matched antibodies (BDIS and Caltag Laboratories) were performed in parallel for each sample and the background staining was subtracted in determining the content of T and NK cells/liver. More than 1 × 10 4 propidium iodide − events were collected.
Results
Analysis of UCB
UCB from the recipient was analyzed for the presence of donor cells by three independent methods. First, flow cytometry was used to detect the presence of NADPH oxidase activity among the UCB granulocytes (Figure 1e and f).
Normal functioning neutrophils were not detected in the newborn infant using two different fluorescent dyes to detect oxidase-derived H 2 O 2 : DHR ( Figure 1 ) or DCF (data not shown). The small amount (0.04%) of brighter cells seen in the PMA stimulated cells were also seen in the unstimulated cells and are, therefore, unlikely to be oxidase specific. Control experiments mixing blood from a normal individual and blood from a known X-linked CGD patient had shown that this flow cytometric assay was capable detecting 0.15% positive cells or one in 667 cells (Figure 1b and c).
The presence of donor cells in the UCB was also analyzed based on the differential expression of HLA class I antigens by the recipient and the paternal donor. GPA − UCB leukocytes were double labeled with anti-HLA-A2 and anti-HLA-B7 to identify both the recipient's cells (HLA-A2 + B7 − ) and the donor cells (HLA-A2 − B7 + ). PBMC from both parents were analyzed as controls (Figure 2a and  b) . The advantage of using a detection method that positively identifies both donor and recipient cells is that cells found to stain with both anti-HLA MoAbs can be identified and disregarded from the analysis. Indeed, non-specific binding of the anti-HLA-B7 MoAb by the recipient's cells led us to use two regions to analyze the data. One region was drawn to encompass most HLA-B7 + cells identified among the donor's PBMC (Figure 2a) . Based on this orthogonal gate (Figure 2d ), HLA-A2 − B7 + cells were detected among UCB leukocytes at a frequency of 0.0912%, after subtracting background staining with the isotype control antibody (Figure 2c) . However, some of the events identified by this gate cannot be definitively identified as being of either recipient or donor origin. The pattern of expression suggests that a slightly higher frequency of HLA-A2
+ cells bound the anti-HLA-B7 MoAb in a nonspecific fashion compared to the mouse IgG1-PE control. Nonetheless, using a rectangular gate to strictly define HLA-A2 − cells, a 0.0023% higher frequency of events was observed relative to the isotype control. 
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The possibility that the few events observed in Figure 2d represent donor cells was further analyzed by enriching for HLA-A2 − UCB leukocytes. UCB leukocytes were depleted of 92.3% of HLA-A2 + cells by immunomagnetic bead depletion and again analyzed for the presence of HLA-A2 − B7 + cells (Figure 2e and f) . There was no enrichment of donor cells in the rectangular region because of the depletion procedure. An increase in the frequency of HLA-B7 + cells was seen using the orthogonal region but, again, the pattern of expression was unlike that of the donor cells in Figure 2a . This analysis suggests that the few potential donor cells observed in Figure 2d are due to non-specific binding of the HLA-B7 MoAb and that no donor leukocytes are present in the UCB.
Analysis of class I HLA antigens was also used to more closely measure the presence of donor cells among UCB T cells and hematopoietic progenitors. T cells were expanded in vitro for 10 days, after which nearly all of the cells expressed high levels of CD3. Events (1 × 10 7 ) were analyzed and no HLA-A2 − B7 + cells were detected (data not shown). These cells were generated from 2.7 × 10 6 GPA − light-density UCB cells used to initiate the culture. The myeloid progeny of progenitors found in the UCB were analyzed after culturing the progenitors for 22 days under defined conditions that support myelopoiesis. At the time of harvest, the cultures contained a mixed population of cells, some of which expressed CD14 and/or CD15. Only 0.0061% of the 700 573 events analyzed were HLA-A2 − B7 + (data not shown). However, the pattern of HLA-B7 expression by most of these cells suggests that they are of host origin and had bound the anti-HLA-B7 MoAb in a non-specific manner. These data, alone, do not provide any convincing evidence of chimerism among the progenitors found in the recipients UCB.
A PCR-based analysis of HLA class II, using specific primers for the mismatch DR15 allele, also showed no donor HLA present among either of the two UCB cell fractions, each run in duplicate PCR reactions (Figure 3c ). This assay was shown to detect 1:1000-1:10 000 cells by controlled mixing studies using DNA from homozygous typing cell lines, therefore, the presence of any donor cells Ͼ0.01% would have been detected (Figure 3a) . Primers specific for all DQB1 alleles used in control PCR reactions to show the integrity of the DNA samples give a correct fragment for all the samples tested (Figure 3b) .
Analysis of peripheral blood and BM at 6 months of age
The peripheral blood of the recipient was analyzed for evidence of chimerism 188 days after birth. Analysis of NADPH oxidase activity among peripheral blood was evaluated with DHR and DCF. Again no functional neutrophils could be identified (Figure 1h) .
Analysis of class I antigens on PBL also failed to detect chimerism (among 2 195 123 events analyzed) above the background seen in the maternal and isotype controls (data not shown). The sensitivity of these flow cytometric analyses was determined by analyzing mixtures of paternal and maternal PBL. The presence of paternal PBL cells among maternal cells was detected at a frequency as low as 0.001%, but a visually discernable population of donor cells required at least a level of 0.01% chimerism (data not shown). Flow cytometric analyses of class I MHC antigens were also used to detect chimerism among BM cells harvested at 6 months of age. Both the light-density (Figure 4a-c) and the high-density (Figure 4d-f ) BM fractions were analyzed. In either fraction, no donor cells were detected above the levels of background staining seen in the isotype controls.
PCR analysis using primers specific for DR15 (the mismatch class II antigen for donor and recipient) was used to show no detectable engrafted antigen in the DNA from peripheral blood as well as BM from the baby (Figure 3c ). Again in these samples DQB1 primers show the DNA to be capable of amplification (Figure 3b) .
Stable chimerism, even at a very low level, is likely to 
Analysis of lymphocyte populations in the fetus at or before 14 weeks gestation
Before 14 weeks gestation the human fetus is considered not to be immunocompetent and, hence, permissive to transplanted cells expressing foreign HLA antigens. 2, 7 However, the functional status of the fetal immune system at different gestational ages remains poorly explored. The lack of engraftment in our patient transplanted at 14 weeks gestation spurred us to analyze the content of lymphocytes in the fetus around this time in gestation. A representative analysis of a 13 weeks gestation liver is shown in Figure 5a . Bone Marrow Transplantation small sample size did not permit us to examine the expression of CD45 on these cells. Hence, the identification of these possible T and NK cells as blood cells could not be confirmed. These data indicate, however, the likely presence of T and NK cells in the fetus at the time that our transplant was performed.
Discussion
A fetus with X-linked CGD was transplanted in utero with paternal CD34
+ Thy-1 + BM cells. No evidence of engraftment was found up to 364 days after the transplant. Evidence for the presence of donor cells was thoroughly sought using a number of techniques capable of detecting a small frequency of donor cells. The presence of functional, donor-derived neutrophils in the UCB and peripheral blood, at 6 months of age, was assessed by flow cytometry using a fluorescent dye to detect functional neutrophils capable of a respiratory burst via NADPH oxidase. No evidence of paternal-derived neutrophils was observed above a level of 0.15%. Class I HLA mismatch between the donor and the recipient was also utilized to distinguish donor and host cell populations by flow cytometry, which was sensitive enough to detect between 0.001% and 0.01% donor cells in peripheral blood. No convincing evidence of donor cells was obtained using this technique to analyze UCB, peripheral blood and a BM sample. The presence of donor cells was also analyzed using a PCR-based assay to detect paternal class II HLA antigens. No donor cell engraftment above a detection level of 0.01% was measured by this method at birth or at 6 months of age. An MLR performed at 6 months of age also failed to provide any evidence of fetal tolerance towards paternal cells, further indicating a lack of hematopoietic chimerism. These data suggest that IUT of an enriched population of paternal stem cells, although safe, is not an effective method of treatment for CGD using current techniques. These findings also challenge the assumption that the fetus is an ideal recipient for HSC transplants.
There has not been a report of clinically significant engraftment for a disease other than SCID or bare lymphocyte syndrome by IUT. 3 We are aware of two other attempts at treating CGD by IUT which have failed to achieve engraftment, although neither of these transplants have been thoroughly documented. 3 One patient transplanted with fetal liver cells died in utero shortly after transplantation and the second patient transplanted with CD34 + -cell enriched paternal BM survived without engraftment. 3, 23 A recent attempt at IUT in a fetus with ␣-thalassemia did result in microchimerism and donor-specific tolerance was suggested by a lack of a response in an MLR. 24 This case is notable in that some engraftment was achieved despite there being no advantage to the donor HSCs and progenitors, as is the case for CGD. The fetus was transplanted with three infusions of CD34 + cells at 13, 19 and 24 weeks gestation. This case suggests that the use of multiple infusions might be more effective at generating chimerism.
One possible explanation for the difficulties in achieving clinically significant levels of chimerism by IUT is a lack of space for the donor HSCs. Despite the tremendous expansion of the hematopoietic system around the time of IUT, there appears to be little space available for donor HSCs. This has been best demonstrated in murine models of IUT. Low levels of chimerism are achieved sporadically in normal mice, [25] [26] [27] whereas in mice homozygous for mutations at the c-kit locus or in SCID mice the levels of chimerism achieved are much higher. 25, 26, 28, 29 It appears that significant chimerism is achieved only when the donor HSCs or their progeny have a competitive advantage over the host cells. 30 Allogeneic and xenogeneic IUT in large animals has had mixed results with some studies achieving clinically significant levels of chimerism [31] [32] [33] [34] [35] [36] whereas others have failed to engraft donor cells above 1%. 37, 38 An explanation for the disparate results in the various animal models is not apparent.
Our findings would indicate that if space is the main barrier to successful IUT, then it is a formidable one. The fetus we transplanted received 1 × 10 7 Thy-1 + CD34 + cells at 14 weeks gestation. The frequency of these cells in fetal liver, the predominant hematopoietic organ at this age, has been measured at 0.16% 20 and the average number of liver cells at 14 weeks gestation is approximately 2 × 10 8 . 39 Thus, the number of Thy-1 + CD34 + cells in the liver at the time our transplant was performed was 3 × 10
5
. This estimate is likely to be somewhat low for the fetus as a whole since progenitors are also in the blood 40 and the BM has begun to develop at this age. 9 Nonetheless, we estimate that our transplant contained of the order of 30-fold more Thy-1 + CD34 + cells than present in the fetus. The lack of engraftment in our case indicates that an excess of HSCs is not likely to displace the resident stem cells of the fetus, as has been suggested to occur in adult mice, 41 unless other barriers to engraftment need also to be considered.
A central premise in the rational for IUT is that the fetus does not have an immune system competent to reject foreign cells. The thymus does not become anatomically mature until 14 weeks gestation at which time peripheral T cells become abundant. 42 This finding has been used to mark the latest time in ontogeny when the IUT is likely to succeed for diseases that do not affect T cell function. However, we demonstrate that T cells can be found in the liver as early as 8 weeks gestation and in the blood at 9 weeks gestation. Likewise, two recent reports have demonstrated T cells in the liver as early as 7 weeks gestation and the blood at 13.5 weeks gestation. These investigators further demonstrated that these fetal T cells were capable of alloreactivity. 43, 44 Although the total number of T cells in the fetus around the time most IUT are performed is likely to be less than the number required to elicit an antigen-specific response, a far greater frequency of T cells react against allogeneic MHC. T cells emerging from the thymus in the weeks following IUT may also react against donor cells if thymic colonization by the donor cells does not occur rapidly. Further study is warranted to determine if T cells contribute to the rejection of donor cells following IUT.
NK cells are also abundant in the fetal liver at the time in gestation that we performed IUT. NK cells have been reported to appear in the liver as early as 6 weeks gestation 45, 46 and their frequency in fetal blood was found to peak at 13 weeks gestation at 29%. 46 NK cells and their progenitors were also detected in the fetal thymus. [47] [48] [49] The functional status of NK cells at the time in ontogeny that we performed the transplant is not known, but fetal NK cells from 15 weeks gestation onward have been found capable of killing various tumor cell lines. 21, 45 The possibility that NK cells may interfere with donor cell engraftment deserves further study as NK cells have been implicated in hematopoietic graft rejection in mice. [50] [51] [52] Pre-treatment of mice with anti-NK cell MoAbs before HSC transplantation has also been reported to increase donor cell engraftment. [53] [54] [55] IUT of NOD/SCID mice, which have a deficiency in NK cell function in addition to other defects, also showed an improved engraftment relative to mice with only the SCID phenotype. 56 IUT remains an experimental form of therapy that may benefit patients with SCID or bare lymphocyte syndrome. The potential for IUT to become an effective form of therapy for other diseases depends on an understanding of the barriers that prevent donor engraftment. Methods of overcoming the potential obstacles of limited space and the fetal immune system need to be devised and tested to ascertain the relative importance of these barriers in achieving donor engraftment. An understanding of the factors that lead to successful engraftment of allogeneic and even xenogeneic HSCs in sheep 3 but not other animal models or humans 2, 3 may also help make IUT a viable form of therapy.
